Form 4: Verona Pharma Director David Ebsworth Acquires 20,000 Ordinary Shares

Director David Ebsworth of Verona Pharma plc acquired 20,000 ordinary shares at a price of $4.44 per share on November 18, 2024.

Summary

• David Ebsworth, a director at Verona Pharma plc, purchased 20,000 ordinary shares on November 18, 2024.
• The purchase price was $4.44 per share.
• Following the transaction, Mr. Ebsworth beneficially owns 940,003 ordinary shares.
• These shares are held directly.
• The ordinary shares are represented by American Depositary Shares (ADSs), with each ADS representing eight ordinary shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as a director purchasing shares is generally seen as a positive sign, but it's a routine transaction.

Positives

• The director's purchase of shares could be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This transaction is a routine disclosure of a director's share purchase and does not indicate any specific industry trend or competitive activity.

Comparison to Industry Standards

• Director share purchases are common and are often seen as a sign of confidence in the company.
• The size of the purchase is not unusual for a director of a publicly traded company.
• Similar transactions are regularly reported by directors of other pharmaceutical companies such as AstraZeneca, GSK, and Pfizer.

Stakeholder Impact

• The share purchase may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Verona Pharma, David Ebsworth, Ordinary Shares, Director, Share Acquisition, ADS, Beneficial Ownership